68Ga-MY6349 PET/CT to detect Trop-2 in solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

68Ga-MY6349 is a new PET radiotracer that targets Trop‑2, a cell-surface protein expressed by many solid tumors. Adult participants with suspected, newly diagnosed, or previously treated solid tumors will undergo contemporaneous 68Ga-MY6349 and standard-of-care 18F-FDG PET/CT for initial staging or recurrence detection. Tumor uptake will be quantified by SUVmax and lesions will be recorded by visual interpretation to count positive findings on each imaging method. The diagnostic accuracy of 68Ga-MY6349 will be calculated and compared directly to standard imaging to see if it reliably identifies Trop‑2 expression.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* adult patients (aged 18 years or older)
* patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report)
* patients who had scheduled both standard-of-care imaging and 68Ga-MY6349 PET/CT scans
* patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee

Exclusion Criteria:

* patients with pregnancy
* the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent

Where it's running

• The First Affiliated Hospital of Xiamen University
  Xiamen, Fujian, China Recruiting

Study contacts

• Study coordinator: Liang Zhao, MD, PhD
• Email: wzhaoliang01@163.com
• Phone: 86 18818350620

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using 68Ga-MY6349 PET/CT to track response to Trop2 antibody‑drug therapy in NSCLC

  This will see if serial 68Ga-MY6349 PET/CT scans can predict how people with metastatic NSCLC respond to Trop2-targeted antibody‑drug treatment.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07151898

• Using 68Ga‑MY6349 PET/CT to track response to Trop2‑targeted therapy in breast cancer

  This study tries to see if repeated 68Ga‑MY6349 PET/CT scans can predict how well Trop2‑targeted antibody‑drug conjugate (Trop2‑ADC) treatment will work for adults with metastatic breast cancer.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07046689

• SumMET: Targeted radioligand therapy for c-MET–positive solid tumors

  This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.

  Recruiting at 2 sites Phase 1/2 Full-Life Technologies UK Limited · Minneapolis, Minnesota and 1 other locations · NCT07873450

• Omni 128 cm PET/CT imaging system: comparing new scanner with standard PET/CT

  This study tests a new Omni 128 cm PET/CT scanner by having adults with a planned clinical PET/CT also undergo an extra research scan to compare image quality.

  Recruiting GE Healthcare · Stanford, California · NCT07857161

• SHR-4595 Injection in Advanced Solid Tumors: Safety, Tolerability, and Dosing in Phase 1

  This early-phase trial tests SHR-4595 injections to see if they are safe and tolerable for adults with advanced solid tumors who have exhausted standard treatments.

  Recruiting at 2 sites Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shenyang, Liaoning and 1 other locations · NCT07830199

• FAPI PET imaging with FAPI-RuiJ and FAPI-04 in solid tumors

  This study tests two FAP-targeted PET tracers (FAPI-RuiJ and FAPI-04) to see which better detects, stages, and monitors solid tumors.

  Recruiting Ruijin Hospital · Shanghai · NCT07776899

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.